CKM
Cardio–Renal–Metabolic Syndrome: Redefining Chronic Disease Through Integrated Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-03-26-PA-09Mar 16, 2026
CKD
The Expanding Therapeutic Landscape in Chronic Kidney Disease
David Alvaro, Ph.D.
Pharma's Almanac
PAO-03-26-PA-07Mar 11, 2026
Partnership
Sever Pharma Solutions Expands Partnership with Silo Pharma on Novel Ketamine-Based Implant for Chronic Pain and Fibromyalgia
Sever Pharma Solutions
PR-08-25-NI-02Aug 11, 2025
Autoimmune Diseases
Pain, Misdiagnosis, and Autoimmune Disease: Untangling Complexity and Bias
Chia Chia Sun; David Alvaro, Ph.D.
Fab Biopharma
PAO-08-25-CL-03Aug 6, 2025
Chronic Diseases
Breaking the Cycle of Chronic Disease with New Therapeutic Strategies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-11Mar 2, 2025
Cannabinoids
Unlocking New Frontiers with Cannabinoid and Psychedelic Therapies
David Alvaro, Ph.D.
Pharma's Almanac
PAO-25-30-04Mar 2, 2025
HLA
Global HLA Typing for Transplant Market to Reach USD 2.1 Billion by 2031, Driven by Advancements in Diagnostic Technologies
Market Research Intellect
PR-10-24-NI-83Nov 7, 2024
Chronic Diseases
Transforming the Management of Chronic Diseases with Biosimilars
Jorge Catella; Hugo Sotelo
Biosidus
PAO-07-24-CL-10Jul 16, 2024
Artificial Intelligence
Using Artificial Intelligence to Get the Right Drug to the Right Patient at the Right Time
Stefan Weiss, M.D.
PAO-05-23-CL-01May 2, 2023
Alzheimer's Disease
Early Targeting of Chronic Inflammation That Precedes and Causes Synaptic Loss
Raymond J. Tesi, M.D.
INmune Bio
PTV-07-21-CL-001Jul 29, 2021
Epigenetics
Epigenetic Regulation to Treat Acute Organ Injury and Chronic Liver Diseases
James E. Brown, D.V.M.
DURECT Corporation
PAP-Q2-20-CL-022Jul 1, 2020
Migraine Therapy
Mimicking Environmental Enrichment for Migraine Therapy
Yuan Zhang, Ph.D.
Seurat Therapeutics
PAP-Q3-19-CL-026Oct 28, 2019
Chronic Migraine
Migraine Drugs Market Size Worth $7.8 Billion by 2025 | CAGR: 18.0%: Grand View Research, Inc.
Grand View Research
PR-M12-18-NI-023Dec 7, 2018
Market Prediction
Migraine Drugs Market Rising at Steady 3.5% During 2017 - 2025; Abortive Treatment Generates Maximum Revenue - TMR
Transparency Market Research
PR-M11-18-NI-011Nov 5, 2018
FDA Approval
New Treatment Option for Migraine Suffers
Emilie Branch
Pharma's Almanac
PAO-M10-18-NI-005Oct 4, 2018
Partnership
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases
Cytotheryx
PR-M08-18-NI-081Aug 21, 2018
Regenerative Medicine Therapies
Ambys Medicines Launches with $140 Million to Pioneer Regenerative Medicine Therapies for Serious Liver Diseases
Cytotheryx
PR-M08-18-NI-079Aug 20, 2018
Prevention Trial
Chronic Migraine Prevention Trial Shows Positive Results for Cefaly® PREVENT Medical Device
Cefaly Technology
PR-M06-18-NI-020Jun 7, 2018
Trial Results
IMBRUVICA® (ibrutinib) Plus GAZYVA® (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
AbbVie
PR-M05-18-NI-102May 28, 2018
FDA Approval
FDA approves new drug for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure
U.S. Food & Drug Administration
PR-M05-18-NI-094May 24, 2018